相关实验视频

Updated: Feb 17, 2026

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

Published on: September 12, 2019

基线CT成像特征与临床指标相结合,预测了HAIC加上向治疗和免疫治疗治疗不可切除的HCC的预后

Haiqin Deng¹, Liu Liu¹, Ziyu Liu¹

¹department of radiology, First Affiliated Hospital of Chongqing Medical University, Chongqing, China.

Abdominal radiology (New York)

|February 16, 2026

概括

对于接受肝动脉输液化疗,向治疗和免疫治疗 (HAIC-TI) 的不可切除肝细胞癌 (uHCC) 患者,基线CT特征和早期反应预测了生存率. 非响应者从额外的HAIC周期中没有显著的生存益处.

科学领域:

在瘤学瘤学.
放射学放射学是一门学科.
医疗成像医学成像

背景情况:

不切除的肝细胞癌 (uHCC) 带来了重大治疗挑战.
肝动脉输液化疗加上向疗法和免疫疗法 (HAIC-TI) 是对HHCC的治疗选择.
预测治疗反应和生存率对于优化患者管理至关重要.

研究的目的:

评估基线对比度增强CT特征和临床指标在接受HAIC-TI的HHCC患者的预后价值.
在这个患者队列中确定早期进展和整体存活率 (OS) 的预测因素.

主要方法:

对132名HHCC患者进行了回顾性分析,这些患者至少接受了两次HAIC-TI.
在两次循环后评估基线对比增强CT特征和mRECIST标准.
对于早期进展预测器的二进制逻辑回归和对OS预测器的Cox回归.

主要成果:

目标应答率 (ORR) 为47.7%,疾病控制率 (DCR) 为86.4%.
在基线CT上非外周洗与早期进展风险较低有关 (OR=0.280).
较短的OS的独立预测因素包括卫星结节,延长的前热血素时间,Child-Pugh类B和不利的早期反应. 更多的HAIC-TI周期预测了更长的OS.

结论:

在基线CT上具有非外周洗模式的患者可能受益于HAIC-TI.
早期治疗反应者表现出明显更好的生存结果.
非响应者没有通过额外的HAIC治疗周期获得有意义的生存优势,这凸显了早期响应评估的重要性.

关键词:

肝动脉输液化疗肝动脉输液化疗肝细胞癌是肝细胞癌.图像处理的特点是图像功能.预测预后预后

更多相关视频

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma

A Three-Dimensional Spheroid Model to Investigate the Tumor-Stromal Interaction in Hepatocellular Carcinoma

Published on: September 30, 2021

Non-Invasive PET/MR Imaging in an Orthotopic Mouse Model of Hepatocellular Carcinoma

Non-Invasive PET/MR Imaging in an Orthotopic Mouse Model of Hepatocellular Carcinoma

Published on: August 31, 2022

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...